Granulocyte Macrophage Colony Stimulating Factor Supplementation in Culture Media for Subfertile Women Undergoing Assisted Reproduction Technologies: A Systematic Review
Author(s) -
Charalampos Siristatidis,
Paraskevi Vogiatzi,
George Salamalekis,
Maria Creatsa,
Nikos Vrachnis,
Demián Glujovsky,
Zoi Iliodromiti,
Charalampos Chrelias
Publication year - 2013
Publication title -
international journal of endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.875
H-Index - 60
eISSN - 1687-8345
pISSN - 1687-8337
DOI - 10.1155/2013/704967
Subject(s) - medicine , blastocyst , andrology , granulocyte macrophage colony stimulating factor , live birth , randomized controlled trial , assisted reproductive technology , cytokine , embryo , pregnancy , embryo quality , embryo culture , gynecology , immunology , in vitro fertilisation , embryogenesis , infertility , biology , microbiology and biotechnology , genetics
Granulocyte macrophage colony stimulating factor (GM-CSF) is a cytokine/growth factor produced by epithelial cells that exerts embryotrophic effects during the early stages of embryo development. We performed a systematic review, and six studies that were performed in humans undergoing assisted reproduction technologies (ART) were located. We wanted to evaluate if embryo culture media supplementation with GM-CSF could improve success rates. As the type of studies and the outcome parameters investigated were heterogeneous, we decided not to perform a meta-analysis. Most of them had a trend favoring the supplementation with GM-CSF, when outcomes were measured in terms of increased percentage of good-quality embryos reaching the blastocyst stage, improved hatching initiation and number of cells in the blastocyst, and reduction of cell death. However, no statistically significant differences were found in implantation and pregnancy rates in all apart from one large multicenter trial, which reported favorable outcomes, in terms of implantation and live birth rates. We propose properly conducted and adequately powered randomized controlled trials (RCTs) to further validate and extrapolate the current findings with the live birth rate to be the primary outcome measure.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom